

Merrill Lynch, Pierce, Fenner & Smith
Incorporated
One Bryant Park
New York, NY 10036

Cowen and Company, LLC
555 California Street, 5th Floor
San Francisco, CA 94104

Leerink Partners, LLC
299 Park Avenue, 21st Floor
New York, NY 10171

May 1, 2015

Re: **Adaptimmune Therapeutics plc**
Registration Statement on Form F-1
Registration File No. 333-203267

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Dear Sir/Madam:

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933 (the "Act"), we, as representatives of the several Underwriters, wish to advise you that 1,855 copies of the Preliminary Prospectus included in the Registration Statement on Form F-1 were distributed during the period April 27 through the date hereof, to prospective underwriters, institutions, dealers and others.

We hereby confirm that we will, and have been informed by the other participating underwriters that they will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934.

In accordance with Rule 461 of the Act, we hereby join in the request of Adaptimmune Therapeutics plc for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 p.m. Eastern time on May 5, 2015, or as soon thereafter as practicable.

[Remainder of page intentionally left blank]

Very truly yours,

By: MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED

By: /s/ Michael Liloia
Name: Michael Liloia
Title: Vice-President

By: COWEN AND COMPANY, LLC

By: /s/ Christopher Weekes
Name: Christopher Weekes
Title: Managing Director

By: LEERINK PARTNERS, LLC

By: /s/ John I. Fitzgerald, Esq.
Name: John I. Fitzgerald, Esq.
Title: Managing Director

[Signature page to Acceleration Request Letter]
